T1	Participants 322 403	Fifty-six patients (49 boys, 7 girls, mean age = 6.4 years, SD = 2.7) enrolled in
T2	Participants 669 819	Thirty-four patients were labeled with Pervasive Developmental Disorder Not Otherwise Specified, and 22 met diagnostic criteria for Autistic Disorder.
T3	Participants 820 882	Forty-five patients were concurrently on other drug treatments
T4	Participants 1150 1269	17 of the most responsive patients from Study 1 began a double-blind trial that also included 8 newly enrolled patients
T5	Participants 1425 1529	Patients from Study 1 entered into Study 2 at an average of 6.5 (SD = 0.8) weeks after beginning Study 1
